Bausch Health up 3% premarket as turnaround continues, guidance raised – Seeking Alpha
Bausch Health Companies (NYSE:BHC) Q3 results:
Revenues: $2,209M (+3.4%); B + L: $1,175M (+2.4%); Salix: $551M (+19.8%); Ortho Dermatologics: $147M (-16.5%).
Xifaxan sales up 24%.
Ne loss: ($49M) (+86.0%); non-GAAP net income: $425M (+5.5%); loss/share: ($…
